Dermatology Medical News about Psoriasis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ustekinumab for the treatment of plaque psoriasis
Expert Review of Dermatology, 10/13/09

Reich K et al. – Recent advances in the understanding of disease pathways in psoriasis indicate an important role of IL–23. Ustekinumab is a first–in–class, fully human IgG1 k monoclonal antibody that binds with high specificity to the p40 subunit of IL–12 and IL–23. It is indicated for the treatment of moderate–to–severe plaque psoriasis in adults who failed, are contraindicated to, or intolerant to other systemic therapies.

<< Previous
Economic hardship associated with managing chronic illness: a...

Next >>
Treatment of pemphigus vulgaris and pemphigus foliaceus